Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.
D Aderka, H Engelmann, Y Maor… - The Journal of …, 1992 - rupress.org
The receptors for tumor necrosis factor (TNF) exist in cell-associated as well as soluble forms,
both binding specifically to TNF. Since the soluble forms of TNF receptors (sTNF-Rs) can …
both binding specifically to TNF. Since the soluble forms of TNF receptors (sTNF-Rs) can …
[HTML][HTML] Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey
…, Z Jafarpour, H Ameen, D Fitzgerald, Y Maor… - The Lancet Global …, 2018 - thelancet.com
Background The Global Point Prevalence Survey (Global-PPS) established an international
network of hospitals to measure antimicrobial prescribing and resistance worldwide. We …
network of hospitals to measure antimicrobial prescribing and resistance worldwide. We …
[HTML][HTML] Multidrug-resistant candida haemulonii and C. Auris, tel aviv, Israel
…, Y Shachor-Meyouhas, S Zakin, Y Maor… - Emerging infectious …, 2017 - ncbi.nlm.nih.gov
Candida auris and C. haemulonii are closely related, multidrug-resistant emerging fungal
pathogens that are not readily distinguishable with phenotypic assays. We studied C. auris …
pathogens that are not readily distinguishable with phenotypic assays. We studied C. auris …
[HTML][HTML] BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
…, M Elbaz, L Nesher, M Stein, Y Maor… - Clinical Microbiology …, 2021 - Elsevier
Objectives The mRNA coronavirus disease 2019 (COVID-19) vaccines have shown high
effectiveness in the prevention of symptomatic COVID-19, hospitalization, severe disease and …
effectiveness in the prevention of symptomatic COVID-19, hospitalization, severe disease and …
[HTML][HTML] Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels …
Y Maor, D Cohen, N Paran, T Israely, V Ezra… - …, 2020 - thelancet.com
Background We assessed outcome of patients with moderate and severe COVID-19 following
treatment with convalescent plasma (CP) and the association with IgG levels in transfused …
treatment with convalescent plasma (CP) and the association with IgG levels in transfused …
Clinical Features of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia versus Those of Methicillin-Resistant S. aureus Bacteremia
Y Maor, M Hagin, N Belausov, N Keller… - The Journal of …, 2009 - academic.oup.com
Background Heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA)
infections are emerging, but their clinical significance remains unclear. Our objective was to …
infections are emerging, but their clinical significance remains unclear. Our objective was to …
Acute renal embolism: forty-four cases of renal infarction in patients with atrial fibrillation
…, M Attali, N Beilinson, M Thaler, M Mouallem, Y Maor… - Medicine, 2004 - journals.lww.com
Acute renal embolus is rarely reported in the medical literature; thus, accurate data regarding
presentation, laboratory tests, diagnostic techniques, and treatment are lacking. To better …
presentation, laboratory tests, diagnostic techniques, and treatment are lacking. To better …
[HTML][HTML] Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2
mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as …
mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as …
[HTML][HTML] Nationwide outbreak of Candida auris infections driven by COVID-19 hospitalizations, Israel, 2021–2022
…, M Hershman-Sarafov, S Maayan, Y Maor… - Emerging Infectious …, 2023 - ncbi.nlm.nih.gov
We report an outbreak of Candida auris across multiple healthcare facilities in Israel. For the
period of May 2014–May 2022, a total of 209 patients with C. auris infection or colonization …
period of May 2014–May 2022, a total of 209 patients with C. auris infection or colonization …
A randomized controlled study assessing convalescent immunoglobulins vs convalescent plasma for hospitalized patients with Coronavirus 2019
Y Maor, E Shinar, M Izak, G Rahav… - Clinical Infectious …, 2023 - academic.oup.com
Background It is unknown whether convalescent immunoglobulins (cIgGs) are better than
convalescent plasma (CP) for patients with coronavirus 2019 (COVID-19). Methods In this …
convalescent plasma (CP) for patients with coronavirus 2019 (COVID-19). Methods In this …